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T
his month’s PLoS Medicine 
publishes a paper describing 
the results of a very early drug 
discovery study. The nature of early 
drug development is to identify many 
promising compounds, only a small 
number of which eventually make it 
into routine treatment. Consequently, 
there are many more papers reporting 
promising leads in early drug 
development than ones that report 
efﬁ  cacy in large clinical trials. Because 
of this natural attrition, medical 
journals (including this one) are 
often reluctant to publish intriguing 
results from the early stages of drug 
discovery. However, PLoS Medicine 
occasionally does publish such reports, 
and the manuscript by Dominique 
Mazier and colleagues [1] in this issue 
is an example. What made us and our 
advisers select this paper above the 
many similar ones we receive?  
As editors, we ask several general 
questions about any submitted 
manuscript: how important is the 
research question (both globally 
and in relation to the journal’s 
audience); what is the likelihood of the 
conclusions holding up over time (and 
when is it worth publishing preliminary 
results that would be important if 
conﬁ  rmed but where conﬁ  rmation is 
uncertain); and, for a highly selective 
general medical journal, do the results 
represent a substantial advance—be 
it in understanding pathogenesis, 
suggesting treatment options, or having 
implications for public health. 
More speciﬁ  cally, for drug 
development papers, questions we 
consider include: how substantial 
is the disease burden that the drug 
would treat; are any treatments 
currently available (or do the available 
treatments have serious limitations); 
has a novel or interesting mechanism 
been developed; (or was a novel system 
used in the development of the drug); 
and ﬁ  nally, is there a realistic path to 
clinical development?
Malaria is clearly a topic of great 
relevance to PLoS Medicine’s mission 
(of publishing papers on the diseases 
causing a high global burden of 
disease), and to our authors and 
readers. A substantial number of 
papers submitted to us concern 
malaria, and the 44 articles of all types 
on malaria that we have published 
have been cumulatively downloaded 
more than 100,000 times. The World 
Health Organization estimates that 
malaria is responsible for more than 1 
million deaths per year, most of them 
young children living in Africa (see 
http:⁄⁄www.who.int/mediacentre/
factsheets/fs094/en/). A recent 
PLoS Medicine paper by Mathers and 
Loncar [2] reported that malaria 
was the 12th leading cause of death 
worldwide in 2002. We also know there 
are substantial limitations of current 
treatments for malaria; resistance to 
antimalarial drugs is an increasing 
problem. Therefore, the development 
of a new drug, especially one targeting 
a stage of the parasite life cycle upon 
which very few other drugs act, is of 
great interest. 
The paper by Mazier and colleagues 
describes the very early stages of such 
a development by identifying a novel 
compound against the liver stage of 
malarial parasites. Before Plasmodium 
spp. can cause the symptoms of malaria 
by multiplying in the bloodstream, the 
parasites must pass through the liver. 
Most current drugs target the blood 
stages. Hopefully, one day malarial 
disease might be prevented by an 
effective vaccine, but it will probably be 
many years before a vaccine that works 
by killing parasites at the liver stages 
of development is available. Another 
option for prevention would be drugs 
that act in the few days between a 
mosquito’s inoculation of a patient with 
sporozoites and the time when parasites 
escape from the liver and develop into 
the blood stages of disease. In severe 
infections, such as those caused by P. 
falciparum, all parasites are released 
from liver cells after a few days, leaving 
none behind. But some Plasmodium 
species (vivax and ovale) can remain in 
liver cells for months, only re-emerging 
after the ﬁ  rst wave of blood-stage 
parasites has produced fevers and thus 
eluding drugs inactive against liver 
stages. In the paper published in this 
issue, Carraz and colleagues applied a 
methodology for screening compounds 
active against the liver stages of P. 
falciparum and identiﬁ  ed an inhibitor 
from aqueous extracts of Madagascan 
plants growing in eastern rain forests. 
Few existing drugs kill liver stages 
of malarial parasites: two such 
drugs licensed at the moment are 
primaquine (an 8-aminoquinoline 
derivative) and the combination of 
atovaquone–proguanil. (Tafenoquine 
and bulaquine, structural relatives of 
primaquine, are not yet licensed.) A 
disadvantage of the 8-aminoquinolines 
is the toxicity caused by haemolysis of 
red blood cells in patients with some 
types of G6PD deﬁ  ciency, a condition 
frequent in African populations. 
In addition to the actual discovery, 
the technical aspects of this paper are 
worthy of note. One problem that has 
beset drug discovery in malaria is the 
difﬁ  culty of culturing the liver stage of 
the parasite in vitro. The effectiveness 
of the 8-aminoquinoline derivatives 
in killing liver stages was discovered 
well before the ﬁ  rst cultures of blood 
stage parasites became possible in 
1976. Since then, several other stages 
of development have been cultured 
in vitro, but culturing these stages is 
technically more challenging than 
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the blood stages. Hence, the work of 
Mazier and colleagues can also be seen 
as a technical achievement, as their 
screening depended on a source of 
sporozoites and primary hepatocyte 
cultures established from liver biopsies. 
Antimalarial efﬁ  cacy of one plant, 
Strychnopsis thouarsii, was initially 
assayed by experiments on P. yoelii (a 
rodent malaria infection) cultured in 
mouse hepatocytes. An extract with 
antimalarial activity in the lower end 
of the micromolar range was further 
analysed and structural analysis of the 
active chemical found a morphinan 
core that was chemically modiﬁ  ed to 
give N-cyclopentyl (NCP)-tazopsine. 
This semi-synthetic derivative was 
shown to have a higher selectivity for 
hepatic parasites, compared with blood 
stages, and was also less toxic to host 
cells than the parent compound. 
Further experiments showed that 
in vivo efﬁ  cacy against sporozoite 
challenge with P. yoelii was conﬁ  rmed 
and found to be best with NCP-
tazopsine. Neither blood stages nor 
gametocytes were killed, conﬁ  rming the 
unique hepatic selectivity of this class 
of antimalarials. One incidental but 
practical advantage of this selectivity 
of tazopsines, which is highlighted by 
the authors, is a diminished chance of 
selecting drug resistance because liver-
stage parasites are much less numerous 
than blood-stage parasites. 
But, even having acknowledged 
this study’s merits, one might still ask 
whether it is reasonable for a general 
medical journal to devote limited 
publication resources to such an early-
phase drug study. We would argue 
that, as failure to produce an effective 
drug is a common event, we should be 
prepared to accept a fair amount of 
uncertainty in such papers, especially 
those presenting technical advances, 
whether or not the particular drug in 
question succeeds.
And the compound that is the 
subject of this study has promise. 
Inhibitors of malaria not only have to 
cross multiple biological membranes 
to reach intra-hepatic parasites, but 
also have to elude metabolism and 
degradation by the very liver cells that 
host the parasite. Tazopsines have 
overcome some of these hurdles. The 
next stage of their development will be 
optimization of the chemically tractable 
lead inhibitor using screening for 
efﬁ  cacy against liver stages of infection. 
Studies of tazopsines on P. vivax and P. 
ovale will also be of interest. 
A truly selective drug would be 
a very welcome tool in the rather 
limited current armamentarium 
against Plasmodium parasites. Gambling 
publication resources on such an 
outcome seems a reasonable decision.  
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